Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL
Boegemann, Martin, Bedke, Jens, Schostak, Martin, Hering-Schubert, Christiane, Welslau, Manfred, Schleicher, Jan, Wolf, Thomas, Petzoldt, Alexander, Doehn, Christian, Grüllich, Carsten, Grünwald, Viktor, Steiner, Thomas, Rogler, Anja, Hanson, Sven, Klein, Dunja, Medinger, Tanja, Goebell, Peter-Juergen
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL
Boegemann, Martin, Bedke, Jens, Schostak, Martin, Welslau, Manfred, Hering-Schubert, Christiane, Wolf, Thomas, Schleicher, Jan, Petzold, Alexander, Doehn, Christian, Grüllich, Carsten, Grünwald, Viktor, Steiner, Thomas, Ehness, Rainer, Klein, Dunja, Medinger, Tanja, Goebell, Peter-Juergen
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article